Oral Berotralstat Treatment for 96 Weeks Consistently Reduces Hereditary Angioedema (HAE) Attack Rates Regardless of Baseline Attack Rate

A goal of prophylactic HAE treatment is to reduce disease burden by decreasing attack rates. Berotralstat is a once daily (QD) prophylactic treatment for HAE. Here we report the long-term efficacy of berotralstat 150mg in patients who completed 96 weeks of treatment in the APeX-2 trial (NCT03485911), stratified by baseline attack rate.